Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Oral Decitabine-Tetrahydrouridine (NDec) in Sickle Cell Disease
NCT05405114Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of decitabine, tetrahydrouridine in sickle cell disease (SCD), sponsored by Novo Nordisk. Started Jul 2022; status: completed.
02
Drugs
decitabinetetrahydrouridine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05405114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405114.